Alex Serafini, PhD

Alex Serafini, PhD has a wealth of experience in the medical and biotechnology fields. In 2015, they served as a Summer Research Intern at Stanford University School of Medicine, where they tested steroidal drugs that targeted glioblastoma multiforme cells with estrogen receptor mutations. In 2017, they were a Graduate Student Researcher at Johns Hopkins Medicine, where they researched potential molecular candidates related to chronic pain after neuropathy. That same year, they were a Teaching Assistant at The Johns Hopkins University, where they guided students on the development of probabilistic discount cash flow models and critiquing student thesis presentations. Alex was also an Equity Research Analyst at The Johns Hopkins University, where they developed financial models for investment purposes using a probabilistic discount cash flow method. In 2018, they were a Scientific Advisor and Head of Scientific Development at MatrixMed Inc., where they co-founded the company and assisted with the initial Family & Friends round. Alex also drafted provisional and non-provisional patents for novel propolis formulations and utility, and managed an initial proof-of-concept Yucatan minipig study. Additionally, they were a Graduate Student Researcher at Icahn School of Medicine at Mount Sinai, where they led two projects associated with the effects of peripheral nerve injuries on brain reward centers and co-led three projects focused on the peripheral nervous system itself. Alex was also an EHHOP Cognitive Behavioral Therapist & Program Director and an EHHOP Mental Health Clinic Pharmacy Chair, where they co-managed ordering, inventorying, and distribution of psychiatric pharmaceuticals. Alex was also an Equity Consultant at AMP Biotech Research, where they performed data acquisition on small/medium cap biotechnology and pharmaceutical companies. Alex was also an Exclusive Contributor (Fini BioInvestments) at Seeking Alpha, where they performed wholistic analysis of several small/medium-cap biotechnology companies. Finally, they were Chief Operating Officer and Chief Executive Officer at Retina Technologies, where they internally managed operations associated with Mount Sinai, including intellectual property preparation, grant filings, and academic outreach. Alex also oversaw non-equity accelerator recruitment and participation, and prepared regulatory crowdfunding legal filings. In 2023, they began working as a Postdoctoral Researcher at Boston University School of Medicine.

Alex Serafini, PhD has a diverse educational background. Alex attended Bellarmine College Preparatory from 2010 to 2014, where they earned their high school diploma. Alex then went on to The Johns Hopkins University from 2014 to 2018, where they earned a BS/MS in Neuroscience. Finally, they are currently enrolled in the Icahn School of Medicine at Mount Sinai, where they are pursuing a Doctor of Philosophy (PhD) in Neuroscience. In addition to their formal education, Alex has obtained several certifications, including Financial Development & Financial Inclusion from the International Monetary Fund (2020), Data Analysis for Life Sciences Professional Certificate from HarvardX (2020), Prescription Drug Regulation, Cost, and Access from HarvardX (2020), Animal Research (Behavior & Surgery) from Johns Hopkins Medicine, Bloomberg Market Concepts from Bloomberg, and CPR from the American Heart Association.